Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

Author： Gonzalez-Barcena D.   Vadillo-Buenfil M.   Cortez-Morales A.   Fuentes-Garcia M.   Cardenas-Cornejo I.   Comaru-Schally A.M.   Schally A.V.  

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.45, Iss.2, 1995-02, pp. : 275-281

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer

By Schellhammer P.   Sharifi R.   Block N.   Soloway M.   Venner P.   Patterson A.L.   Sarosdy M.   Vogelzang N.   Jones J.   Kolvenbag G.  

Urology, Vol. 45, Iss. 5, 1995-05 ,pp. : 745-752

Elsevier

Access to resources Recommend Favorite

Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer

By Sakurai Kenichi   Matsuo Sadanori   Enomoto Katsuhisa   Amano Sadao   Shiono Motomi  

Surgery Today, Vol. 41, Iss. 1, 2011-01 ,pp. : 48-53

Springer Publishing Company

Access to resources Recommend Favorite

Protection of the germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a luteinizing hormone-releasing hormone agonist and antiandrogen therapy

By Cespedes R.D.   Peretsman S.J.   Thompson I.M.   Jackson C.  

Urology, Vol. 46, Iss. 5, 1995-11 ,pp. : 688-691

Elsevier

Access to resources Recommend Favorite

Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer

By Kobayashi Takashi   Nishizawa Koji   Mitsumori Kenji  

Scandinavian Journal of Urology and Nephrology, Vol. 40, Iss. 3, 2006-05 ,pp. : 198-203

Informa Healthcare

Access to resources Recommend Favorite

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer - implications for dosing schedule and neoadjuvant study consideration

By Hall M.C.   Fritzsch R.J.   Sagalowsky A.I.   Ahrens A.   Petty B.   Roehrborn C.G.  

Urology, Vol. 53, Iss. 5, 1999-05 ,pp. : 898-902

Elsevier

Access to resources Recommend Favorite